July 25, 2018
1 min read
Save

Compound shows significant potential as Alzheimer’s disease modifier

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Bryostatin, a compound that showed an ability to induce synaptogenesis and prevent neuronal death in pretrials, now shows potential as a modifier of Alzheimer’s disease in patients who were memantine-naive, according to data presented at the Alzheimer’s Association International Conference.

Researchers, led by Richard Thompson, PhD, of the biostatistics department at Johns Hopkins University, randomly assigned 150 such patients in a 1:1:1 ratio to receive either 20 µg of bryostatin (Neurotope Bioscence Inc.), 40 µg of bryostatin, or placebo weekly every 2 weeks for 11 weeks.

They found the patients who received 20 µg bryostatin and were memantine-naive had positive multiple severe impairment battery scores starting at week 5, and scores were maintained for the entire study follow-up period of 30 days after a patient received their last dose. At the end of that period, these patients had a 6.1-point difference in their severe impairment battery scores vs. those who received placebo (95% CI, 1.5-10.7). There was no treatment effect observed in patients who received monotherapy with memantine.

“Data from many other laboratories over the years implicating [N-Nitrosodimethylamine] in memory processing could now take on new meaning from Neurotrope’s clinical results with bryostatin — in the absence of memantine,” Daniel Alkon, MD, president and chief scientific officer, Neurotrope, said in a press release. – by Janel Miller

Reference: Thompson R, et al. Significant cognitive improvement with bryostatin for advanced Alzheimer’s patients in the absence of memantine. Presented at: Alzheimer’s Association International Conference; July 22-26, 2018; Chicago.

Disclosure: Alkon is president and chief scientific officer at Neurotope. Healio Family Medicine was unable to determine the other authors' relevant financial disclosures prior to publication.